87 results
10-K
2024 FY
EX-23.1
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated September 30, 2024, with respect
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
of the pathophysiology of the disease. Having two drugs with independent mechanisms of action increases the likelihood of the drugs having a synergistic effect … of Schedule I controlled substances, which would include our lead drug candidates, IHL-42X, PSX-001 and IHL- 675A;
authorization from an independent
10-K
2024 FY
EX-19.1
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
for small transactions or transactions that may seem necessary or justifiable for independent reasons, such as the need to raise money for an emergency
10-K
2024 FY
EX-10.9
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
, the Committee may seek advice from an independent advisor as to whether the discretion should be exercised and if so then the alternative extent of vesting
8-K
EX-10.2
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
by an independent appraiser selected in good faith by the Requisite Holders and reasonably acceptable to the Company, the fees and expenses of which shall be paid … that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation
8-K
EX-10.1
kngiwd wv
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
S-1/A
EX-4.2
s64kfr8n4 5p920
17 Jul 24
IPO registration (amended)
8:47am
S-1/A
ivekj
17 Jul 24
IPO registration (amended)
8:47am
S-1/A
EX-23.1
k6crberwc
17 Jul 24
IPO registration (amended)
8:47am
S-1/A
EX-4.3
s9p6r
17 Jul 24
IPO registration (amended)
8:47am
S-1/A
EX-10.9
g0mqs2r6p
17 Jul 24
IPO registration (amended)
8:47am
S-1
na2nk zlbvnn
3 Jul 24
IPO registration
6:29am
S-1
EX-23.1
uw6r r3wsc1ngudg
3 Jul 24
IPO registration
6:29am
8-K
EX-10.1
wvp1b
5 Mar 24
Departure of Directors or Certain Officers
6:11am
8-K
662a6bnk39 5c
5 Mar 24
Departure of Directors or Certain Officers
6:11am
10-Q
EX-10.14
t64vxhgrixv pce5b
14 Feb 24
Quarterly report
6:16am
8-K
EX-99.1
gu53ep she90bpa
18 Jan 24
Other Events
9:08am
8-K
EX-99.1
ufuzpc c3ab5
17 Jan 24
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
6:05am
S-8
EX-5.1
t0bd3 wcemk
20 Dec 23
Registration of securities for employees
5:05pm
S-8
EX-23.2
xv79y 8gg7
20 Dec 23
Registration of securities for employees
5:05pm